This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Multimeric Biotherapeutics, Inc.
Drug Names(s): SP-D-CD40L
Description: UltraCD40L (SP-D-CD40L) is a 4-trimer form of CD40 ligand (CD40L) formed by fusing the body of surfactant protein D (SP-D) with the receptor-binding domain of CD40L that stimulates the immune system.
Multimeric and UCSD
In April 2011, Multimeric Biotherapeutics obtained an exclusive worldwide license from the University of California San Diego (UCSD) to all therapeutic uses of the UltraLigand technology for producing highly active many-trimer molecules from the TNFSF protein family.
The basis of the technology is the realization that many TNFSF ligands are only active when produced as many-trimer multimers. Of these molecules, the most advanced is a 4-trimer form of CD40 ligand (CD40L). This molecule, UltraCD40L, is formed by fusing the body of surfactant protein D (SP-D) with the receptor-binding domain of CD40L. A related 2-trimer protein, MegaCD40L, is formed by fusing the body of Acrp30 (adiponectin) with the receptor-binding domain of CD40L. These and related molecules in the UltraLigand and MegaLigand families have been shown to enhance vaccine responses (adjuvant activity) and induce curative anticancer immunity in animal models.
Pink Sheet Weekly Trademark Review Dec. 27, 2016
Additional information available to subscribers only: